

# Grünenthal

[View the current Grünenthal Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/23112-Gr%FCnenthal.html>)

## Contact Details:

Via Correggio, 43  
Milano

Tel: 39-02-43051

Fax: 39-02-430555

Email: [dg@grunenthal.com](mailto:dg@grunenthal.com)

20149

Italy

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società. L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

## Recent Publications by Grünenthal:



- [Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.](#)  
*Tapentadol exerts its analgesic effects through micro opioid receptor...* 17th October, 2009  
Grunenthal- Drugs Today (Barc). 2009 Jul;45(7):483-96. ([DOI Direct Link](#))
- [Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors.](#)  
*AIM/METHODS: In vitro binding tests to human receptors and in vivo...* 11th July, 2009  
Preclinical Development, Grunenthal GmbH, Aachen, Germany.- Pharmacology. 2009;84(2):74-81.  
Epub 2009 Jul 3. ([DOI Direct Link](#))
- [Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes.](#)  
*The new analgesic tapentadol was evaluated for induction and inhibition of...* 13th May, 2009  
Grunenthal GmbH- Drug Metab Lett. 2008 Jan;2(1):67-75.
- [Participation of representatives for patients in the Federal Joint Committee. Results of qualitative](#)

[interviews\]](#)

- The GMG (Law Modernizing the German Health Care System) was introduced in...* 10th March, 2009  
Universitat- Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 ([DOI Direct Link](#))
- [A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative \(bunionectomy\) pain \\*](#)  
*ABSTRACT Objective: This study evaluated tapentadol immediate release (IR)...* 11th February, 2009  
aPremier Research, Austin, TX, USA, bJohnson & Johnson Pharmaceutical- Curr Med Res Opin. 2009  
Feb 10. ([DOI Direct Link](#))
  - [Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.](#)  
*OBJECTIVE: This study set out to assess the cost effectiveness of using a...* 7th January, 2009  
Grunenthal- Clin Drug Investig. 2008;28(9):583-601.
  - [Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.](#)  
*BACKGROUND: Tapentadol is a novel, centrally acting analgesic with two...* 31st December, 2008  
Grunenthal GmbH, Zieglerstr. 6 52078, Aachen, Germany.- Anesth Analg. 2008 Dec;107(6):2048-55. ([DOI Direct Link](#))
  - [Differential effects of morphine on the affective and the sensory component of carrageenan-induced nociception in the rat.](#)  
*Pain is generally considered to have a sensory and an affective component...* 8th July, 2008  
Grunenthal GmbH, Preclinical Research and Development, Department of- Pain. 2008  
Jun;136(3):373-9. Epub 2007 Sep 6. ([DOI Direct Link](#))
  - [Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice.](#)  
*The function of the transient receptor potential vanilloid 1 (TRPV1)...* 11th April, 2008  
Preclinical Research and Development, Department of Pharmacology,- Mol Cell Neurosci. 2008  
Mar;37(3):579-89. Epub 2007 Dec 15. ([DOI Direct Link](#))
  - [Effect of 2-methyl-6-\(phenylethynyl\) pyridine on intravenous self-administration of ketamine and heroin in the rat.](#)  
*The mGluR5 antagonist 2-methyl-6-(phenylethynyl) pyridine (MPEP) may be...* 25th January, 2008  
Grunenthal GmbH, Preclinical Research and Development, Department of- Behav Pharmacol. 2007  
Dec;18(8):717-24. ([DOI Direct Link](#))
  - [Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.](#)  
*PURPOSE: This prospective observational noninterventional study aimed at...* 4th January, 2008  
Grunenthal GmbH, Medical Department, 52099 Aachen, Germany.- Contraception. 2007  
Aug;76(2):84-90. Epub 2007 Jun 11. ([DOI Direct Link](#))
  - [Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects.](#)  
*Tapentadol is a novel, centrally acting oral analgesic with a dual mode of...* 28th December, 2007  
Grunenthal GmbH, Preclinical Research and Development/Department of- Eur J Drug Metab  
Pharmacokinet. 2007 Jul-Sep;32(3):163-9.
  - [\(-\)-\(1R,2R\)-3-\(3-dimethylamino-1-ethyl-2-methyl-propyl\)-phenol hydrochloride \(tapentadol HCl\): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.](#)  
*(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol...* 6th November, 2007  
Department of Pharmacology, Grunenthal GmbH, Aachen, Germany.- J Pharmacol Exp Ther. 2007  
Oct;323(1):265-76. Epub 2007 Jul 26. ([DOI Direct Link](#))
  - [Measuring reward with the conditioned place preference \(CPP\) paradigm: update of the last decade.](#)  
*Conditioned place preference (CPP) continues to be one of the most popular...* 1st November, 2007  
Grunenthal GmbH, Preclinical Research and Development, Department of- Addict Biol. 2007  
Sep;12(3-4):227-462. ([DOI Direct Link](#))

- [Gruenenthal to focus on pain-relief drugs](#)

*Therapeutics Daily: Oct 16 2009 12:30PM Matching: gruenenthal*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

